Desvenlafaxine succinate_product_DataBase

Bioactivity	Desvenlafaxine succinate, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine succinate (DVS) shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter[1][2].
Target	IC50: 47.3 nM (hSERT), 531.3 nM (hNET).
Invitro	Desvenlafaxine succinate has the potential to inhibit CYP2D6, which could result in increased concentrations of drugs metabolized through this pathway. Desvenlafaxine succinate also induces CYP3A4, which could impact the metabolism of drugs metabolized via this enzyme[2].
In Vivo	Desvenlafaxine succinate (30 mg/kg, orally) significantly increases extracellular NE levels but had no effect on DA levels using microdialysis[1]. Animal Model:
Name	Desvenlafaxine succinate
CAS	448904-47-0
Formula	C20H31NO6
Molar Mass	381.46
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Darlene C Deecher, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. [2]. Michael A Sopko Jr, et al. Desvenlafaxine: another "me too" drug? Ann Pharmacother. 2008 Oct;42(10):1439-46.

PeptideDB